Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

p>New ZILVER(R) PTX(TM) Clinical Data. In April 2009 we announced that our partner Cook Medical Inc. ("Cook") had reported data that showed that 82 percent of patients who were treated with Cook's ZILVER PTX paclitaxel-eluting peripheral stent were free from reintervention at two-year follow up. The ZILVER PTX Registry study, involving 792 patients globally, is assessing the safety and efficacy of the ZILVER PTX in treating peripheral artery disease. The most recent results were reported at the 31st International Symposium Charing Cross Controversies Challenges Consensus. Data was compiled at 12 and 24 months for 593 patients and 177 patients respectively. The registry, which enrolled a broad spectrum of patients, includes patients with complex lesions (e.g., long lesions, total occlusions, in-stent restenosis). The corresponding event-free survival rates were 87 percent and 78 percent, and freedom from target lesion revascularization was 89 percent and 82 percent. Clinical measures that included ankle-brachial index, Rutherford score, and walking distance and speed scores showed significant improvement at six and 12 months and were maintained through 24 months. Detailed evaluation of stent x-rays demonstrated excellent stent integrity through 12 months, confirming previously published results showing 99 percent completely intact stents (less than 1 percent stent fracture rates observed) with a mean follow up of 2.4 years in the challenging superior femoral artery and popliteal arteries, including behind the knee locations.

    Financial Information
    ---------------------

This press release contains financial data derived from the condensed financial statements derived from the unaudited consolidated interim financial statements for the three-month periods ended June 30, 2009, and 2008. Full unaudited consolidated interim financial statements and Management's Discussion and Analysis for the three-month periods ended June
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Reston, VA (PRWEB) July 28, 2014 ... leading nonprofit authority on the use of health IT ... its Health Plan Identifier (HPID) Workgroup has ... Between a Health Plan and Payer?” The HPID Workgroup, ... worked closely with the Centers for Medicare and Medicaid ...
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... Hershey, PA & Boston, MA (PRWEB) July 28, 2014 ... into collaboration agreements with two researchers to further develop ... and deadly malignant brain tumor, in combination with their ... executed by ITI and Duke University, are based on ... MHSc, Chief, Division of Neurosurgery at The Preston Robert ...
(Date:7/28/2014)... The global market for biotechnology is expected ... a new study by Grand View Research, Inc. Increasing ... vaccines and drugs in an attempt to improve healthcare ... to drive market demand over the next six years. ... the use of genetically engineered seeds is expected to ...
Breaking Biology Technology:WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Global Synthetic Biology Market 2014-2018 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 2String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 3String of Collaborations Launch Immunomic Therapeutics’ Brain Tumor Program Pipeline 4Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4
... March 14, 2011 Argentum Medical, LLC today issued a ... versus Noble Biomaterials, Inc. "The most important thing ... patents and it is business as usual for Argentum," said ... case concerned non-patent issues and is currently being appealed. We ...
... Biofuels, a bioenergy crop company using breeding and biotechnology ... it is applying more than 1.6 million genetic markers ... of marker assisted selection (MAS) methods to produce elite, ... the announcement during its presentation at the Biowise 2011 ...
... March 11, 2011 /PRNewswire-Asia-FirstCall/ --Tianyin Pharmaceutical Co., Inc. (NYSE ... specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, ... at the 23rd ROTH Annual OC Growth Stock Conference ... Carlton in Dana Point, California. Dr. James ...
Cached Biology Technology:Argentum Medical Issues Response to Recent Decision in Litigation With Noble Biomaterials 2SG Biofuels Advances Jatropha Biotech Platform with Application of Genetic Markers to Reference Genome 2TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011 2
(Date:7/28/2014)... Roald Amundsen became the first man to reach the ... years later, an international team of scientists led by ... proven that air pollution from industrial activities arrived long ... from widely spaced locations around the Antarctic continent, including ... and precise reconstruction to date of lead pollution over ...
(Date:7/27/2014)... asteroid strike that wiped them out if it had ... say. , A fresh study using up-to-date fossil records ... a new narrative of the prehistoric creatures, demise, some ... the few million years before a 10km-wide asteroid struck ... This included extensive volcanic activity, changing sea levels and ...
(Date:7/27/2014)... discovered a new species of mayfly in the southern Western ... In fact, this is the first time that any mayfly ... in peninsular India. , The new species, called Labiobaetis ... for his substantial contribution to the understanding of the Ephemeroptera ... a study that describes the new mayfly in the ...
Breaking Biology News(10 mins):Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3Dinosaurs fell victim to perfect storm of events, study shows 2
... by researchers at Baylor College of Medicine (BCM) and ... DNA sequencing to the patient's bedside, the doctor's office ... battlefield. , "We could eventually do direct detection of ... performed in the laboratory, said Dr. Michael L. Metzker, ...
... in the March 30th edition of the prestigious scientific journal ... UK's national academy of science) shows that the transfer of ... is much larger and more extensive than previously believed. , ... in a contentious debate. It is the first to isolate ...
... "A Method of Reconstituting Nucleic Acid Molecules" today to ... of DermaPlus, Inc. The patent covers methods for recovering ... allow scientists to reassemble everything from prehistoric, extinct animals ... applied by our scientists, brings us closer to our ...
Cached Biology News:Color-blind method opens new doors in DNA sequencing 2Color-blind method opens new doors in DNA sequencing 3Researchers reveal the infectious impact of salmon farms on wild salmon 2Researchers reveal the infectious impact of salmon farms on wild salmon 3Researchers reveal the infectious impact of salmon farms on wild salmon 4Dinosaur DNA? New Patent Covers Degraded DNA recovery 2
Kit includes your choice of reagents for labeling 3 x 10 9 cells and EasySep magnet....
... the efficient enrichment of functional endoplasmic ... cell culture. The isolated ER are ... metabolic pathway analysis. Metabolic abnornalities of ... children, cystic fibrosis and many more ...
... for stabilizing 50g of purified RNA samples for ... delivers all of the advantages and applications you ... the RNA can be used for enzymatic applications ... has been optimised for the stabilization of aqueous ...
Human SEAP ORF, provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
Biology Products: